ID   APC11_HUMAN             Reviewed;          84 AA.
AC   Q9NYG5; A8MTT2; B7ZW64; Q502X9; Q9BW64; Q9P0R2;
DT   29-AUG-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   10-MAY-2017, entry version 159.
DE   RecName: Full=Anaphase-promoting complex subunit 11;
DE            Short=APC11;
DE   AltName: Full=Cyclosome subunit 11;
DE   AltName: Full=Hepatocellular carcinoma-associated RING finger protein;
GN   Name=ANAPC11; ORFNames=HSPC214;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=11573242; DOI=10.1002/jcb.1217;
RA   Chan A.H., Lee S.M.Y., Chim S.S., Kok L.D., Waye M.M.Y., Lee C.Y.,
RA   Fung K.P., Tsui S.K.W.;
RT   "Molecular cloning and characterization of a RING-H2 finger protein,
RT   ANAPC11, the human homolog of yeast Apc11p.";
RL   J. Cell. Biochem. 83:249-258(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Li N., Wan T., Zhang W., Cao X.;
RT   "Novel human APC11 anaphase-promoting complex subunit.";
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Umbilical cord blood;
RX   PubMed=11042152; DOI=10.1101/gr.140200;
RA   Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G.,
RA   Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W.,
RA   Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.;
RT   "Cloning and functional analysis of cDNAs with open reading frames for
RT   300 previously undefined genes expressed in CD34+ hematopoietic
RT   stem/progenitor cells.";
RL   Genome Res. 10:1546-1560(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain, Skin, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   IDENTIFICATION IN APC/C COMPLEX.
RX   PubMed=10922056; DOI=10.1073/pnas.97.16.8973;
RA   Gmachl M., Gieffers C., Podtelejnikov A.V., Mann M., Peters J.-M.;
RT   "The RING-H2 finger protein APC11 and the E2 enzyme UBC4 are
RT   sufficient to ubiquitinate substrates of the anaphase-promoting
RT   complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:8973-8978(2000).
RN   [7]
RP   FUNCTION, MUTAGENESIS, AND INTERACTION WITH ANAPC2 AND UBE2D2.
RX   PubMed=11739784; DOI=10.1091/mbc.12.12.3839;
RA   Tang Z., Li B., Bharadwaj R., Zhu H., Oezkan E., Hakala K.,
RA   Deisenhofer J., Yu H.;
RT   "APC2 cullin protein and APC11 RING protein comprise the minimal
RT   ubiquitin ligase module of the anaphase-promoting complex.";
RL   Mol. Biol. Cell 12:3839-3851(2001).
RN   [8]
RP   FUNCTION OF THE APC/C.
RX   PubMed=18485873; DOI=10.1016/j.cell.2008.04.012;
RA   Jin L., Williamson A., Banerjee S., Philipp I., Rape M.;
RT   "Mechanism of ubiquitin-chain formation by the human anaphase-
RT   promoting complex.";
RL   Cell 133:653-665(2008).
RN   [9]
RP   ELECTRON MICROSCOPY OF THE APC/C.
RX   PubMed=16364912; DOI=10.1016/j.molcel.2005.11.008;
RA   Dube P., Herzog F., Gieffers C., Sander B., Riedel D., Mueller S.A.,
RA   Engel A., Peters J.-M., Stark H.;
RT   "Localization of the coactivator Cdh1 and the cullin subunit Apc2 in a
RT   cryo-electron microscopy model of vertebrate APC/C.";
RL   Mol. Cell 20:867-879(2005).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (7.4 ANGSTROMS) OF THE APC/C, AND
RP   SUBUNIT.
RX   PubMed=25043029; DOI=10.1038/nature13543;
RA   Chang L., Zhang Z., Yang J., McLaughlin S.H., Barford D.;
RT   "Molecular architecture and mechanism of the anaphase-promoting
RT   complex.";
RL   Nature 513:388-393(2014).
CC   -!- FUNCTION: Together with the cullin protein ANAPC2, constitutes the
CC       catalytic component of the anaphase promoting complex/cyclosome
CC       (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls
CC       progression through mitosis and the G1 phase of the cell cycle.
CC       The APC/C complex acts by mediating ubiquitination and subsequent
CC       degradation of target proteins: it mainly mediates the formation
CC       of 'Lys-11'-linked polyubiquitin chains and, to a lower extent,
CC       the formation of 'Lys-48'- and 'Lys-63'-linked polyubiquitin
CC       chains. May recruit the E2 ubiquitin-conjugating enzymes to the
CC       complex. {ECO:0000269|PubMed:11739784,
CC       ECO:0000269|PubMed:18485873}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: The mammalian APC/C is composed of 14 distinct subunits
CC       that assemble into a complex of at least 19 chains with a combined
CC       molecular mass of around 1.2 MDa. Interacts with the cullin domain
CC       of ANAPC2. Interacts with UBE2D2. {ECO:0000269|PubMed:10922056,
CC       ECO:0000269|PubMed:11739784, ECO:0000269|PubMed:25043029}.
CC   -!- INTERACTION:
CC       Q9NZC7-5:WWOX; NbExp=4; IntAct=EBI-12224467, EBI-12040603;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:11573242}.
CC       Nucleus {ECO:0000269|PubMed:11573242}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NYG5-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NYG5-2; Sequence=VSP_012347;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed at high levels in skeletal muscle
CC       and heart; in moderate levels in brain, kidney, and liver; and at
CC       low levels in colon, thymus, spleen, small intestine, placenta,
CC       lung and peripheral blood leukocyte.
CC       {ECO:0000269|PubMed:11573242}.
CC   -!- DOMAIN: The RING-type zinc finger domain coordinates an additional
CC       third zinc ion.
CC   -!- PTM: Auto-ubiquitinated.
CC   -!- SIMILARITY: Belongs to the RING-box family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF36134.1; Type=Frameshift; Positions=67; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF247565; AAF65816.1; -; mRNA.
DR   EMBL; AF247789; AAL95694.1; -; mRNA.
DR   EMBL; AF151048; AAF36134.1; ALT_FRAME; mRNA.
DR   EMBL; AC145207; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000607; AAH00607.2; -; mRNA.
DR   EMBL; BC066308; AAH66308.1; -; mRNA.
DR   EMBL; BC095454; AAH95454.1; -; mRNA.
DR   EMBL; BC104641; AAI04642.1; -; mRNA.
DR   EMBL; BC171892; AAI71892.1; -; mRNA.
DR   EMBL; BC171898; AAI71898.1; -; mRNA.
DR   EMBL; BC171899; AAI71899.1; -; mRNA.
DR   EMBL; BC171900; AAI71900.1; -; mRNA.
DR   CCDS; CCDS11789.1; -. [Q9NYG5-1]
DR   CCDS; CCDS32769.1; -. [Q9NYG5-2]
DR   RefSeq; NP_001002244.1; NM_001002244.2. [Q9NYG5-2]
DR   RefSeq; NP_001002245.1; NM_001002245.2. [Q9NYG5-1]
DR   RefSeq; NP_001002246.1; NM_001002246.2. [Q9NYG5-1]
DR   RefSeq; NP_001002247.1; NM_001002247.2. [Q9NYG5-1]
DR   RefSeq; NP_001002248.1; NM_001002248.2. [Q9NYG5-1]
DR   RefSeq; NP_001002249.1; NM_001002249.2. [Q9NYG5-1]
DR   RefSeq; NP_001276343.1; NM_001289414.1. [Q9NYG5-1]
DR   RefSeq; NP_001276344.1; NM_001289415.1. [Q9NYG5-1]
DR   RefSeq; NP_001276345.1; NM_001289416.1. [Q9NYG5-1]
DR   RefSeq; NP_001276346.1; NM_001289417.1. [Q9NYG5-1]
DR   RefSeq; NP_001276349.1; NM_001289420.1.
DR   RefSeq; NP_057560.8; NM_016476.11. [Q9NYG5-1]
DR   UniGene; Hs.534456; -.
DR   PDB; 2MT5; NMR; -; A=17-84.
DR   PDB; 4R2Y; X-ray; 1.76 A; A/B/C/D=17-84.
DR   PDB; 4UI9; EM; 3.60 A; B=1-84.
DR   PDB; 5A31; EM; 4.30 A; B=1-84.
DR   PDB; 5G04; EM; 4.00 A; B=1-84.
DR   PDB; 5G05; EM; 3.40 A; B=1-84.
DR   PDB; 5JG6; X-ray; 2.00 A; A/D=17-84.
DR   PDB; 5KHR; EM; 6.10 A; B=1-84.
DR   PDB; 5L9T; EM; 6.40 A; B=1-84.
DR   PDB; 5L9U; EM; 6.40 A; B=1-84.
DR   PDB; 5LCW; EM; 4.00 A; B=1-84.
DR   PDBsum; 2MT5; -.
DR   PDBsum; 4R2Y; -.
DR   PDBsum; 4UI9; -.
DR   PDBsum; 5A31; -.
DR   PDBsum; 5G04; -.
DR   PDBsum; 5G05; -.
DR   PDBsum; 5JG6; -.
DR   PDBsum; 5KHR; -.
DR   PDBsum; 5L9T; -.
DR   PDBsum; 5L9U; -.
DR   PDBsum; 5LCW; -.
DR   ProteinModelPortal; Q9NYG5; -.
DR   SMR; Q9NYG5; -.
DR   BioGrid; 119591; 33.
DR   DIP; DIP-52741N; -.
DR   IntAct; Q9NYG5; 27.
DR   iPTMnet; Q9NYG5; -.
DR   PhosphoSitePlus; Q9NYG5; -.
DR   BioMuta; ANAPC11; -.
DR   DMDM; 19924286; -.
DR   EPD; Q9NYG5; -.
DR   MaxQB; Q9NYG5; -.
DR   PeptideAtlas; Q9NYG5; -.
DR   PRIDE; Q9NYG5; -.
DR   Ensembl; ENST00000344877; ENSP00000339695; ENSG00000141552. [Q9NYG5-1]
DR   Ensembl; ENST00000357385; ENSP00000349957; ENSG00000141552. [Q9NYG5-2]
DR   Ensembl; ENST00000392376; ENSP00000376181; ENSG00000141552. [Q9NYG5-1]
DR   Ensembl; ENST00000571024; ENSP00000461648; ENSG00000141552. [Q9NYG5-1]
DR   Ensembl; ENST00000571570; ENSP00000458143; ENSG00000141552. [Q9NYG5-1]
DR   Ensembl; ENST00000571874; ENSP00000459200; ENSG00000141552. [Q9NYG5-1]
DR   Ensembl; ENST00000572639; ENSP00000460678; ENSG00000141552. [Q9NYG5-1]
DR   Ensembl; ENST00000572851; ENSP00000458265; ENSG00000141552. [Q9NYG5-1]
DR   Ensembl; ENST00000574924; ENSP00000460064; ENSG00000141552. [Q9NYG5-1]
DR   Ensembl; ENST00000575195; ENSP00000458515; ENSG00000141552. [Q9NYG5-1]
DR   Ensembl; ENST00000577747; ENSP00000463567; ENSG00000141552. [Q9NYG5-1]
DR   Ensembl; ENST00000578550; ENSP00000464615; ENSG00000141552. [Q9NYG5-1]
DR   Ensembl; ENST00000579978; ENSP00000463640; ENSG00000141552. [Q9NYG5-1]
DR   Ensembl; ENST00000583839; ENSP00000463598; ENSG00000141552. [Q9NYG5-1]
DR   GeneID; 51529; -.
DR   KEGG; hsa:51529; -.
DR   UCSC; uc002kbv.3; human. [Q9NYG5-1]
DR   CTD; 51529; -.
DR   DisGeNET; 51529; -.
DR   GeneCards; ANAPC11; -.
DR   HGNC; HGNC:14452; ANAPC11.
DR   HPA; HPA021989; -.
DR   HPA; HPA027838; -.
DR   MIM; 614534; gene.
DR   neXtProt; NX_Q9NYG5; -.
DR   OpenTargets; ENSG00000141552; -.
DR   PharmGKB; PA24787; -.
DR   GeneTree; ENSGT00550000075186; -.
DR   HOGENOM; HOG000171951; -.
DR   HOVERGEN; HBG097038; -.
DR   InParanoid; Q9NYG5; -.
DR   KO; K03358; -.
DR   OMA; CCPDCPL; -.
DR   PhylomeDB; Q9NYG5; -.
DR   TreeFam; TF354219; -.
DR   Reactome; R-HSA-141430; Inactivation of APC/C via direct inhibition of the APC/C complex.
DR   Reactome; R-HSA-174048; APC/C:Cdc20 mediated degradation of Cyclin B.
DR   Reactome; R-HSA-174084; Autodegradation of Cdh1 by Cdh1:APC/C.
DR   Reactome; R-HSA-174154; APC/C:Cdc20 mediated degradation of Securin.
DR   Reactome; R-HSA-174178; APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1.
DR   Reactome; R-HSA-174184; Cdc20:Phospho-APC/C mediated degradation of Cyclin A.
DR   Reactome; R-HSA-176407; Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase.
DR   Reactome; R-HSA-176408; Regulation of APC/C activators between G1/S and early anaphase.
DR   Reactome; R-HSA-176409; APC/C:Cdc20 mediated degradation of mitotic proteins.
DR   Reactome; R-HSA-176412; Phosphorylation of the APC/C.
DR   Reactome; R-HSA-179409; APC-Cdc20 mediated degradation of Nek2A.
DR   Reactome; R-HSA-2467813; Separation of Sister Chromatids.
DR   Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SIGNOR; Q9NYG5; -.
DR   UniPathway; UPA00143; -.
DR   GeneWiki; ANAPC11; -.
DR   GenomeRNAi; 51529; -.
DR   PRO; PR:Q9NYG5; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000141552; -.
DR   CleanEx; HS_ANAPC11; -.
DR   ExpressionAtlas; Q9NYG5; baseline and differential.
DR   Genevisible; Q9NYG5; HS.
DR   GO; GO:0005680; C:anaphase-promoting complex; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0097602; F:cullin family protein binding; IDA:MGI.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:MGI.
DR   GO; GO:0034450; F:ubiquitin-ubiquitin ligase activity; IDA:MGI.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0031145; P:anaphase-promoting complex-dependent catabolic process; TAS:Reactome.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0007067; P:mitotic nuclear division; TAS:UniProtKB.
DR   GO; GO:0051436; P:negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0051437; P:positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition; TAS:Reactome.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; TAS:Reactome.
DR   GO; GO:0070979; P:protein K11-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; TAS:Reactome.
DR   GO; GO:0051439; P:regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle; TAS:Reactome.
DR   CDD; cd00162; RING; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR024991; Apc11.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   Pfam; PF12861; zf-ANAPC11; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell cycle; Cell division;
KW   Complete proteome; Cytoplasm; Metal-binding; Mitosis; Nucleus;
KW   Reference proteome; Ubl conjugation; Ubl conjugation pathway; Zinc;
KW   Zinc-finger.
FT   CHAIN         1     84       Anaphase-promoting complex subunit 11.
FT                                /FTId=PRO_0000055747.
FT   ZN_FING      34     77       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   METAL        23     23       Zinc 1. {ECO:0000250}.
FT   METAL        26     26       Zinc 1. {ECO:0000250}.
FT   METAL        34     34       Zinc 3. {ECO:0000250}.
FT   METAL        37     37       Zinc 3. {ECO:0000250}.
FT   METAL        44     44       Zinc 3. {ECO:0000250}.
FT   METAL        51     51       Zinc 2. {ECO:0000250}.
FT   METAL        53     53       Zinc 2. {ECO:0000250}.
FT   METAL        56     56       Zinc 1. {ECO:0000250}.
FT   METAL        58     58       Zinc 3. {ECO:0000250}.
FT   METAL        59     59       Zinc 1. {ECO:0000250}.
FT   METAL        73     73       Zinc 2. {ECO:0000250}.
FT   METAL        76     76       Zinc 2. {ECO:0000250}.
FT   VAR_SEQ      38     84       KVPGDDCPLVWGQCSHCFHMHCILKWLHAQQVQQHCPMCRQ
FT                                EWKFKE -> PLHGESISRCLGWCPQPVPVLGGRAHPQVPI
FT                                NTASPTPGQHTGSLMSREESSRSPDPTPPALDQETSSLLRC
FT                                TSPWCLDHSCDLFGITDQVSADGPRACRQGARRRLPAGVGP
FT                                VLPLLPHALHPQVAARTAGAAALPHVPPGMEVQGVRPDLAL
FT                                AGGAS (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_012347.
FT   MUTAGEN      23     23       C->S: Greatly reduces autoubiquitination
FT                                activity; in isoform 1.
FT                                {ECO:0000269|PubMed:11739784}.
FT   MUTAGEN      26     26       C->S: Greatly reduces autoubiquitination
FT                                activity; in isoform 1.
FT                                {ECO:0000269|PubMed:11739784}.
FT   MUTAGEN      34     34       C->S: Slightly reduces autoubiquitination
FT                                activity; in isoform 1.
FT                                {ECO:0000269|PubMed:11739784}.
FT   MUTAGEN      37     37       C->S: Slightly reduces autoubiquitination
FT                                activity; in isoform 1.
FT                                {ECO:0000269|PubMed:11739784}.
FT   MUTAGEN      44     44       C->S: Slightly reduces autoubiquitination
FT                                activity; in isoform 1.
FT                                {ECO:0000269|PubMed:11739784}.
FT   MUTAGEN      51     51       C->S: Greatly reduces autoubiquitination
FT                                activity; in isoform 1.
FT                                {ECO:0000269|PubMed:11739784}.
FT   MUTAGEN      53     53       H->S: Greatly reduces autoubiquitination
FT                                activity; in isoform 1.
FT                                {ECO:0000269|PubMed:11739784}.
FT   MUTAGEN      56     56       H->S: Greatly reduces autoubiquitination
FT                                activity; in isoform 1.
FT                                {ECO:0000269|PubMed:11739784}.
FT   MUTAGEN      58     58       H->S: Slightly reduces autoubiquitination
FT                                activity; in isoform 1.
FT                                {ECO:0000269|PubMed:11739784}.
FT   MUTAGEN      59     59       C->S: Greatly reduces autoubiquitination
FT                                activity; in isoform 1.
FT                                {ECO:0000269|PubMed:11739784}.
FT   MUTAGEN      73     73       C->S: Greatly reduces autoubiquitination
FT                                activity; in isoform 1.
FT                                {ECO:0000269|PubMed:11739784}.
FT   MUTAGEN      76     76       C->S: Greatly reduces autoubiquitination
FT                                activity; in isoform 1.
FT                                {ECO:0000269|PubMed:11739784}.
FT   STRAND        3      9       {ECO:0000244|PDB:5G05}.
FT   STRAND       19     22       {ECO:0000244|PDB:5G05}.
FT   TURN         24     26       {ECO:0000244|PDB:4R2Y}.
FT   HELIX        35     37       {ECO:0000244|PDB:4R2Y}.
FT   TURN         38     41       {ECO:0000244|PDB:4R2Y}.
FT   STRAND       46     49       {ECO:0000244|PDB:4R2Y}.
FT   STRAND       50     52       {ECO:0000244|PDB:2MT5}.
FT   STRAND       54     56       {ECO:0000244|PDB:4R2Y}.
FT   HELIX        57     67       {ECO:0000244|PDB:4R2Y}.
FT   STRAND       68     70       {ECO:0000244|PDB:5JG6}.
FT   STRAND       76     79       {ECO:0000244|PDB:4R2Y}.
SQ   SEQUENCE   84 AA;  9841 MW;  EACBD5A54FDC11AE CRC64;
     MKVKIKCWNG VATWLWVAND ENCGICRMAF NGCCPDCKVP GDDCPLVWGQ CSHCFHMHCI
     LKWLHAQQVQ QHCPMCRQEW KFKE
//
